Intra-Cellular Therapies Inc.
March 20, 2024 - by Joey Ramson
$ITCI, which takes an intracellular approach to deliver treatments that will be transformative for people living with complex psychiatric and neurologic diseases, looks to have some possible support at around $64 in the short term. The company’s flagship drug, CAPLYTA, saw a 63% increase in the number of psychiatrists prescribing it in 2023 and is currently seeking FDA approval to expand CAPLYTA’s use to treat Major Depressive Disorder as well.
